AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Up To Nine Adalimumab Biosimilars to Launch In Key Year

Billion_Dollar
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock

More from Biosimilars

More from Products